ORIGINAL ARTICLE   

Minerva Cardiology and Angiology 2021 June;69(3):261-8

DOI: 10.23736/S2724-5683.20.05138-5

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Outcomes of the novolimus-eluting bioresorbable vascular scaffold in real world clinical practice

Beytullah CAKAL ✉, Sinem CAKAL, Oguz KARACA, Mehmet O. OMAYGENC, Filiz K. YILMAZ, Haci M. GUNES, Ozgur U. OZCAN, Ersin İBISOGLU, Bilal BOZTOSUN

Department of Cardiology, Faculty of Medicine, Istanbul Medipol University, Bagcilar, Istanbul

BACKGROUND: Most of the current data regarding the use of bioresorbable scaffolds (BRS) come from everolimus-eluting stent platforms. Adverse events with the everolimus-eluting BRSs which are the most comprehensively characterized BRS, hampered the clinical use of other BRS. There is paucity of published data regarding long term use of novolimus-eluting BRS.
METHODS: This study sought to evaluate the performance of novolimus-eluting BRS device at midterm follow-up in real world clinical practice. One hundred and forty-four patients (mean age 57.5±9.7 years, 78.5% male) treated with 206 scaffolds between October 2015 and December 2017 were enrolled. A device-oriented composite endpoint (DOCE) comprising cardiac death, target vessel myocardial infarction (TV-MI), clinically driven target lesion revascularization (TLR) and rate of scaffold thrombosis were investigated.
RESULTS: During a mean follow-up of 33±9 months, DOCE occurred in 9 patients (6.3%) of which cardiac death occurred in 2 patients (1.4%), and clinically driven TLR in 7 patients (4.9%), TV-MI in one patient. Target vessel revascularization (TVR) was observed in nine patients. None of the patients experienced scaffold thrombosis.
CONCLUSIONS: The use of novolimus-eluting BRS in this real-world population achieved good clinical outcomes.

KEY WORDS: Percutaneous coronary intervention; Cardiovascular system; Novolimus